临界可切除/局部晚期胰腺癌全程新辅助治疗的反应预测因素、围术期结局与生存
结果显示R0切除率高但影像学降期少见,仅延长化疗周期(≥6周期)、化疗后CA19-9最佳反应和主要病理缓解独立预测生存延长。
要点
- TNT后R0切除率达94%,但影像学解剖降期仅28%。
- 延长化疗≥6周期、CA19-9最佳反应和主要病理缓解独立预测生存延长。
- 三项因素均达标者生存更优,每缺失一项则生存受损。
核心结论
- TNT治疗后可切除的临界可切除/局部晚期胰腺癌患者中,尽管影像学降期率低,但R0切除率高。
- 延长化疗周期、化疗后CA19-9最佳反应和主要病理缓解独立预测术后生存延长。
主要发现
- 165例(85%)使用FOLFIRINOX,65例(34%)使用吉西他滨联合白蛋白紫杉醇,36例(19%)在长程放化疗前更换化疗方案。
- 影像学解剖降期28%,125例(65%)需联合静脉和/或动脉切除,94%达到R0切缘。
- 90天主要并发症发生率36%,死亡率6.7%。
- 排除手术死亡后,中位无复发生存期23.5个月,总生存期58.8个月;1年、2年、3年无复发生存率分别为65%、48%、32%,总生存率分别为96%、78%、62%。
关键数值与推荐
- 延长化疗定义为≥6周期。
- 三项独立生存预测因素:延长化疗(≥6周期)、化疗后CA19-9最佳反应、主要病理缓解。
- 三项因素均达标者生存更优,每缺失一项则生存受损。
临床怎么用
- 考虑将初始化疗周期延长至≥6周期以使CA19-9正常化或达到完全代谢反应。
- 若未达到上述反应,可考虑更换化疗方案,再行放化疗和手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify predictive factors associated with operative morbidity, mortality, and survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) undergoing total neoadjuvant therapy (TNT). BACKGROUND: The optimal preoperative treatment sequencing for BR/LA PDA is unknown. TNT, or systemic chemotherapy followed by chemoradiation (CRT), addresses both occult metastases and positive margin risks and thus is a potentially optimal strategy; however, factors predictive of perioperative and survival outcomes are currently undefined. METHODS: We reviewed our experience in BR/LA patients undergoing resection from 2010 to 2017 following TNT assessing operative morbidity, mortality, and survival in order to define outcome predictors and response endpoints. RESULTS: One hundred ninety-four patients underwent resection after TNT, including 123 (63%) BR and 71 (37%) LA PDAC. FOLFIRINOX or gemcitabine along with nab-paclitaxel were used in 165 (85%) and 65 (34%) patients, with 36 (19%) requiring chemotherapeutic switch before long-course CRT and subsequent resection. Radiologic anatomical downstaging was uncommon (28%). En bloc venous and/or arterial resection was required in 125 (65%) patients with 94% of patients achieving R0 margins. The 90-day major morbidity and mortality was 36% and 6.7%, respectively. Excluding operative mortalities, the median, 1-year, 2-year, and 3-year recurrence-free survival (RFS) [overall survival (OS)] rates were 23.5 (58.8) months, 65 (96)%, 48 (78)%, and 32 (62)%, respectively. Radiologic downstaging, vascular resection, and chemotherapy regimen/switch were not associated with survival. Only 3 factors independently associated with prolonged survival, including extended duration (≥6 cycles) chemotherapy, optimal post-chemotherapy CA19-9 response, and major pathologic response. Patients achieving all 3 factors had superior survival outcomes with a survival detriment for each failing factor. In a subset of patients with interval metabolic (PET) imaging after initial chemotherapy, complete metabolic response highly correlated with major pathologic response. CONCLUSION: Our TNT experience in resected BR/LA PDAC revealed high negative margin rates despite low radiologic downstaging. Extended duration chemotherapy with associated biochemical and pathologic responses highly predicted postoperative survival. Potential modifications of initial chemotherapy treatment include extending cycle duration to normalize CA19-9 or achieve complete metabolic response, or consideration of chemotherapeutic switch in order to achieve these factors may improve survival before moving forward with CRT and subsequent resection.
引用
- Truty MJ, Kendrick ML, Nagorney DM, et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021. PMID: 30946090. doi:10.1097/SLA.0000000000003284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。